Skip to main content
Premium Trial:

Request an Annual Quote

Scott Zajac, Bob Moore, Jonathan Foltz, Jason A. Rifkin, Ronald D. Henriksen, Marshall G. Cox

SBA Honors Advantage Capital’s Scott Zajac as Financial Services Champion
Scott Zajac, senior managing director of Advantage Capital Partners, has been named Financial Services Champion of the Year by the US Small Business Administration's St. Louis District.
Zajac was honored for his role in Advantage Capital’s support of a $32 million small business loan program for low-income entrepreneurs who would not otherwise qualify for conventional bank loans. The program was part of the private equity firm’s effort to assist entrepreneurs through the federal New Markets Tax Credit program, which provides tax credits for up to $16 billion of private-sector investment in economically distressed communities nationwide.
Among businesses that have benefited from Advantage Capital financing under the New Markets program are Singulex, a Hayward, Calif., developer of a single-molecule detection technology to enable disease understanding and research; and Kereos, a St. Louis developer of targeted molecular imaging agents and therapeutics to treat cancer and heart disease.
Zajac joined Advantage Capital Partners in 1996 and is involved in the firm's investment analysis and monitoring activities and sits on the boards of several Advantage Capital portfolio companies. He received a master's degree in information systems from Washington University, an MBA from St. Louis University and a bachelor's degree from the University of Missouri. A certified treasury manager, Zajac previously worked at AG Edwards & Sons and Citicorp Mortgage.
SBA’s Financial Services Champion award recognizes individuals who assist small businesses through advocacy efforts to increase the usefulness and availability of accounting or financial services.

Silicon Border Taps Bob Moore as Business Development VP
Bob Moore has joined Silicon Border Development in San Diego as vice president of business development. Moore was previously director of sales operations and business development for Dubai Silicon Oasis, where he was responsible for bringing in a number of technology companies to Dubai’s first technology park.
Moore has held positions with Dongbu Anam Semiconductor Operations in South Korea, Redwood MicroSystems, SCP Global, Intel, Integrated Device Technology, and NCR.
Silicon Border is a 10,000-acre high-technology science park planned for Mexicali, Mexico. The 15-square-mile park is intended to support biotechnology as well as the semiconductor, flat panel display, solar, and aerospace industries.

Delcath Welcomes Returning Executive VP, New VP-Business Development
Jonathan Foltz has rejoined Delcath Systems, a drug delivery company based in Stamford, Conn., in the newly created position of executive vice president.
Foltz was director of operations at Delcath from 1992 to 2001, and was instrumental in bringing the company from its formative stage through its initial public offering in October 2000. Foltz had worked with Delcath in an advisory position since February. Previously he was president of Os Technology, a women’s health medical device company which he co-founded. Foltz, a chartered financial analyst, received a BS in finance and computer science from Lehigh University and an MBA from the University of Connecticut.
“With momentum building in our clinical trials and a management committed to expanding the company’s technology, I believe the shareholders and, ultimately, the patients will benefit from our work in the months ahead,” Foltz said in the company’s May 24 statement announcing two personnel appointments.
Delcath also named Jason A. Rifkin to the newly created position of vice president of business development. Rifkin recently earned a masters degree in biotechnology from the University of Pennsylvania’s School of Engineering and Applied Sciences.
Rifkin was previously an attorney with Fox Rothschild, where he was an associate in the corporate department’s pharmaceuticals and biotechnology group. Rifkin received a BA from the University of Pennsylvania and a JD from Northeastern University School of Law.

Henriksen Named Cytori’s Interim Chairman As Cox Retires
Ronald Henriksen, an independent director of Cytori Therapeutics in San Diego, has been named interim chairman by the company’s board of directors following the retirement May 3 of Marshall Cox from the board. Cox, who now provides consulting services to Cytori, was recognized as chairman emeritus for his founding efforts and 10 years of dedicated service as board chairman.
Henriksen joined Cytori as director in 2002. He is currently the chief investment officer of Twilight Ventures Partners; chairman of the board of Semafore Pharmaceuticals; CEO of EndGenitor Technologies; and a director for QLT, Canada's largest biopharmaceutical company.
Cytori is a developer of stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery, and other conditions deemed serious, chronic, or life threatening.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.